Feed / SRTA

Strata Critical Medical, Inc.

SRTA

Healthcare · 5.13 -1.6% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Strata Critical Medical, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Company-1.6% todayVolume comparison unavailable
Market group0 of 19 activeIndustrial Equipment & Services · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • SRTA's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if SRTA's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Care Facilities

No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • SRTA's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods7
Price observations319
Usable filing statements98
Verified relationships4
Evidence supporting the case
  • Latest annual revenue changed +34.3% year over year.
  • Operating margin changed +4.0 percentage points in the latest annual period.
  • Net margin changed +39.6 percentage points in the latest annual period.
Evidence challenging the case
  • Diluted shares increased 5.9% in the latest annual period.
  • Operating cash flow was only -1.183x net income in the latest annual period.
Questions before a position
  • P/E is 32% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

5.13
6m+19.7%12m+11.9%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-09-30$50.5M+115.6%$-0.93
2022-12-31$146.1M+189.2%$-0.38
2023-12-31$225.2M+54.1%$-0.76+3.2%
2024-12-31$146.8M-34.8%$-0.35+5.4%
2025-12-31$197.1M+34.3%$0.50+5.9%

What management says matters

Persistent and emerging business drivers

Demand and volumemixed · 2 filings
Such developments could lead to increased operating expenses, pricing pressure, reduced margins, delays or cancellations of organ transport missions, and reduced demand for our services, any of which could materially adversely affect our business, financial c…
10-K · Mar 3, 2026
Legal and regulatory exposuremixed · 2 filings
Such an incident could involve actual or alleged misconduct, operational failures, or regulatory enforcement actions, and could lead to reputational harm, reduced demand for our services, and increased scrutiny from regulators or customers.
10-K · Mar 3, 2026
Foreign exchangemixed · 1 filings
The following table summarizes our cash flows for the periods indicated: Three Months Ended March 31, 2026 2025 (in thousands) Net cash provided by / (used in) operating activities $ 3,885 $ (246) Net cash provided by investing activities 24,729 20,407 Net ca…
10-Q · May 6, 2026
Pricing and mixnegative · 1 filings
Such developments could lead to increased operating expenses, pricing pressure, reduced margins, delays or cancellations of organ transport missions, and reduced demand for our services, any of which could materially adversely affect our business, financial c…
10-K · Mar 3, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 2.1× · EV/sales 2.0×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

5.13-1.6% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for SRTA. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for SRTA. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind SRTA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

JOBYJoby Aviation, Inc.partnerMay 6, 2026

The Passenger business acquired by Joby Buyer consisted of the Company’s business of offering, selling, promoting, marketing, planning, booking, brokering, coordinating and arranging the transportation of passengers on aircraft operated by other entities and…

JOBYJoby Aviation, Inc.customerNov 10, 2025

The Passenger business acquired by the Joby Buyer pursuant to the Joby Purchase Agreement consisted of the Company’s business of offering, selling, promoting, marketing, planning, booking, brokering, coordinating and arranging the transportation of passengers…

Depended on by

JOBYJoby Aviation, Inc.investeeNov 6, 2025

Acquisitions On August 29, 2025, the Company completed the acquisition of 100 % of the outstanding equity of Blade Urban Air Mobility, Inc., a wholly owned subsidiary of Strata Critical Medical, Inc, f/k/a Blade Air Mobility, Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SRTA is currently a Follower in the organic co-movement group Industrial Equipment & Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for SRTA; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.